1.Nodular lymphocyte-predominant Hodgkin's lymphoma of the parotid gland: A case report
Jacqueline Rose E. Agustin ; Jomell C. Julian
Philippine Journal of Internal Medicine 2025;63(1):64-67
INTRODUCTION
Parotid lymphoma is a rare occurrence, let alone a diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Salivary gland tumors commonly affect the parotid gland, although a primary malignant lesion rarely occurs, with an incidence of 0.5 to 3.0/100,000 population/year worldwide. This case report describes the presentation of this rare lymphoma. This also demonstrates the efficacy of standard of care chemotherapy with doxorubicin, vincristine, bleomycin, and dacarbazine with an anti-CD20 monoclonal antibody, rituximab (R-ABVD).
CASEThis is a case of a 44-year-old male with a gradually enlarging right preauricular mass. Biopsy and immunohistochemical staining confirmed a diagnosis of NLPHL Stage IIA. A total of six cycles of chemotherapy with R-ABVD was given. Follow-up PET CT showed resolution of FDG avid nodes localized near the surgically removed parotid gland, confirming complete remission.
DISCUSSIONParotid malignancy only accounts for 5% of all head and neck tumors. NLPHL is even more rare, with an incidence of 1.5/1,000,000 population per year. The rarity of the case limits clinical trials for its treatment. Because of this, R-ABVD has been employed as a treatment of choice for intermediate-staged NLPHL. Overall response showed an 85% five-year progression-free survival and 99% overall survival.
CONCLUSIONThis case report highlights the significance of early lymphoma detection despite its rarity among parotid tumors and prompt initiation of chemotherapy.
Human ; Male ; Adult: 25-44 Yrs Old ; Lymphocytes ; Hodgkin Disease
2.Expression of CD226 in the small intestinal group 3 innate lymphoid cells (ILC3) in mice.
Lu YANG ; Jingchang MA ; Yitian LIU ; Tingting WANG ; Yuling WANG ; Ran ZHUANG ; Zhengxiang ZHANG
Chinese Journal of Cellular and Molecular Immunology 2024;40(1):1-6
		                        		
		                        			
		                        			Objective To observe the expression of adhesion molecule CD226 on the small intestinal group 3 innate lymphoid cells (ILC3) in mice. Methods The bioinformatics was used to analyze the expression of CD226 on murine ILCs. Small intestinal mucosal lamina propria lymphocytes (LPL) were isolated from wild-type C57BL/6J mice, and the expression of CD226 on ILC1 and ILC3 was detected by flow cytometry. A mouse model of dextran sulfate sodium (DSS)-induced colitis was constructed to observe the changes in the expression of CD226 on ILC3. Results Both ILC1 and ILC3 in the mice small intestine expressed CD226 molecules; the proportion of ILC3 was reduced, while the expression level of CD226 on ILC3 was increased in the colitis model. Conclusion CD226 is expressed on the small intestines of mice, and although the proportion of ILC3 decreases in the DSS-induced colitis, the expression of CD226 on ILC3 increases.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Colitis/chemically induced*
		                        			;
		                        		
		                        			Immunity, Innate
		                        			;
		                        		
		                        			Intestine, Small
		                        			;
		                        		
		                        			Lymphocytes
		                        			;
		                        		
		                        			Mice, Inbred C57BL
		                        			
		                        		
		                        	
3.The number of FOXP3+regulatory T cells (Tregs) decreased and transformed into RORγt+FOXP3+Tregs in lung tissues of mice with bronchopulmonary dysplasia.
Langyue HE ; Hongyan LU ; Ying ZHU ; Jianfeng JIANG ; Huimin JU ; Yu QIAO ; Shanjie WEI
Chinese Journal of Cellular and Molecular Immunology 2024;40(1):7-12
		                        		
		                        			
		                        			Objective To explore the phenotypic conversion of regulatory T cells (Tregs) in the lungs of mice with bronchopulmonary dysplasia (BPD)-affected mice. Methods A total of 20 newborn C57BL/6 mice were divided into air group and hyperoxia group, with 10 mice in each group. The BPD model was established by exposing the newborn mice to hyperoxia. Lung tissues from five mice in each group were collected on postnatal days 7 and 14, respectively. Histopathological changes of the lung tissues was detected by HE staining. The expression level of surfactant protein C (SP-C) in the lung tissues was examined by Western blot analysis. Flow cytometry was performed to assess the proportion of FOXP3+ Tregs and RORγt+FOXP3+ Tregs in CD4+ lymphocytes. The concentrations of interleukin-17A (IL-17A) and IL-6 in lung homogenate were measured by using ELISA. Spearman correlation analysis was used to analyze the correlation between FOXP3+Treg and the expression of SP-C and the correlation between RORγt+FOXP3+ Tregs and the content of IL-17A and IL-6. Results The hyperoxia group exhibited significantly decreased levels of SP-C and radical alveolar counts in comparison to the control group. The proportion of FOXP3+Tregs was reduced and that of RORγt+FOXP3+Tregs was increased. IL-17A and IL-6 concentrations were significantly increased. SP-C was positively correlated with the expression level of RORγt+FOXP3+ Tregs. RORγt+FOXP3+ Tregs and IL-17A and IL-6 concentrations were also positively correlated. Conclusion The number of FOXP3+ Tregs in lung tissue of BPD mice is decreased and converted to RORγt+ FOXP3+ Tregs, which may be involved in hyperoxy-induced lung injury.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Mice, Inbred C57BL
		                        			;
		                        		
		                        			Bronchopulmonary Dysplasia
		                        			;
		                        		
		                        			T-Lymphocytes, Regulatory
		                        			;
		                        		
		                        			Interleukin-17
		                        			;
		                        		
		                        			Nuclear Receptor Subfamily 1, Group F, Member 3
		                        			;
		                        		
		                        			Hyperoxia
		                        			;
		                        		
		                        			Interleukin-6
		                        			;
		                        		
		                        			Forkhead Transcription Factors
		                        			;
		                        		
		                        			Lung
		                        			
		                        		
		                        	
4.Research progress on mTOR signaling pathway and regulatory T cell nutrition metabolic regulation mechanism.
Chinese Journal of Cellular and Molecular Immunology 2024;40(1):69-73
		                        		
		                        			
		                        			In the tumor microenvironment, metabolic reprogramming can impact metabolic characteristics of T cells, thus inducing immunosuppression to promote tumor immune escape. The mammalian target of rapamycin (mTOR) signaling pathway plays an important role in regulating diverse functions of various immune cells. This review mainly focuses on the molecular mechanism of mTOR signaling in regulating cellular energy metabolism process, and the activation status of mTOR signaling under different nutritional environments. In addition, it also summarizes the role of the mTOR signaling in regulatory T cell (Tregs) metabolism and function in current studies, and evaluates the potential of mTOR as a clinical immunotherapeutic target and its current application challenges.
		                        		
		                        		
		                        		
		                        			Immunosuppression Therapy
		                        			;
		                        		
		                        			Metabolic Reprogramming
		                        			;
		                        		
		                        			Signal Transduction
		                        			;
		                        		
		                        			Sirolimus
		                        			;
		                        		
		                        			T-Lymphocytes, Regulatory
		                        			;
		                        		
		                        			TOR Serine-Threonine Kinases
		                        			;
		                        		
		                        			Humans
		                        			
		                        		
		                        	
5.TREM-2 Drives Development of Multiple Sclerosis by Promoting Pathogenic Th17 Polarization.
Siying QU ; Shengfeng HU ; Huiting XU ; Yongjian WU ; Siqi MING ; Xiaoxia ZHAN ; Cheng WANG ; Xi HUANG
Neuroscience Bulletin 2024;40(1):17-34
		                        		
		                        			
		                        			Multiple sclerosis (MS) is a neuroinflammatory demyelinating disease, mediated by pathogenic T helper 17 (Th17) cells. However, the therapeutic effect is accompanied by the fluctuation of the proportion and function of Th17 cells, which prompted us to find the key regulator of Th17 differentiation in MS. Here, we demonstrated that the triggering receptor expressed on myeloid cells 2 (TREM-2), a modulator of pattern recognition receptors on innate immune cells, was highly expressed on pathogenic CD4-positive T lymphocyte (CD4+ T) cells in both patients with MS and experimental autoimmune encephalomyelitis (EAE) mouse models. Conditional knockout of Trem-2 in CD4+ T cells significantly alleviated the disease activity and reduced Th17 cell infiltration, activation, differentiation, and inflammatory cytokine production and secretion in EAE mice. Furthermore, with Trem-2 knockout in vivo experiments and in vitro inhibitor assays, the TREM-2/zeta-chain associated protein kinase 70 (ZAP70)/signal transducer and activator of transcription 3 (STAT3) signal axis was essential for Th17 activation and differentiation in EAE progression. In conclusion, TREM-2 is a key regulator of pathogenic Th17 in EAE mice, and this sheds new light on the potential of this therapeutic target for MS.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			CD4-Positive T-Lymphocytes/pathology*
		                        			;
		                        		
		                        			Cell Differentiation
		                        			;
		                        		
		                        			Encephalomyelitis, Autoimmune, Experimental/metabolism*
		                        			;
		                        		
		                        			Mice, Inbred C57BL
		                        			;
		                        		
		                        			Multiple Sclerosis
		                        			;
		                        		
		                        			Th1 Cells/pathology*
		                        			
		                        		
		                        	
6.γδ T cells: Major advances in basic and clinical research in tumor immunotherapy.
Yueqi ZHAO ; Peng DONG ; Wei HE ; Jianmin ZHANG ; Hui CHEN
Chinese Medical Journal 2024;137(1):21-33
		                        		
		                        			
		                        			γδ T cells are a kind of innate immune T cell. They have not attracted sufficient attention because they account for only a small proportion of all immune cells, and many basic factors related to these cells remain unclear. However, in recent years, with the rapid development of tumor immunotherapy, γδ T cells have attracted increasing attention because of their ability to exert cytotoxic effects on most tumor cells without major histocompatibility complex (MHC) restriction. An increasing number of basic studies have focused on the development, antigen recognition, activation, and antitumor immune response of γδ T cells. Additionally, γδ T cell-based immunotherapeutic strategies are being developed, and the number of clinical trials investigating such strategies is increasing. This review mainly summarizes the progress of basic research and the clinical application of γδ T cells in tumor immunotherapy to provide a theoretical basis for further the development of γδ T cell-based strategies in the future.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Receptors, Antigen, T-Cell, gamma-delta
		                        			;
		                        		
		                        			Immunotherapy, Adoptive
		                        			;
		                        		
		                        			T-Lymphocytes
		                        			;
		                        		
		                        			Immunotherapy
		                        			;
		                        		
		                        			Neoplasms/therapy*
		                        			
		                        		
		                        	
7.Understanding endometriosis from an immunomicroenvironmental perspective.
Dian FAN ; Xu WANG ; Zhixian SHI ; Yuting JIANG ; Bohao ZHENG ; Lian XU ; Shengtao ZHOU
Chinese Medical Journal 2023;136(16):1897-1909
		                        		
		                        			
		                        			Endometriosis, a heterogeneous, inflammatory, and estrogen-dependent gynecological disease defined by the presence and growth of endometrial tissues outside the lining of the uterus, affects approximately 5-10% of reproductive-age women, causing chronic pelvic pain and reduced fertility. Although the etiology of endometriosis is still elusive, emerging evidence supports the idea that immune dysregulation can promote the survival and growth of retrograde endometrial debris. Peritoneal macrophages and natural killer (NK) cells exhibit deficient cytotoxicity in the endometriotic microenvironment, leading to inefficient eradication of refluxed endometrial fragments. In addition, the imbalance of T-cell subtypes results in aberrant cytokine production and chronic inflammation, which contribute to endometriosis development. Although it remains uncertain whether immune dysregulation represents an initial cause or merely a secondary enhancer of endometriosis, therapies targeting altered immune pathways exhibit satisfactory effects in preventing disease onset and progression. Here, we summarize the phenotypic and functional alterations of immune cells in the endometriotic microenvironment, focusing on their interactions with microbiota and endocrine and nervous systems, and how these interactions contribute to the etiology and symptomology of endometriosis.
		                        		
		                        		
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Endometriosis/metabolism*
		                        			;
		                        		
		                        			Killer Cells, Natural/metabolism*
		                        			;
		                        		
		                        			T-Lymphocytes/metabolism*
		                        			;
		                        		
		                        			Estrogens
		                        			;
		                        		
		                        			Endometrium/metabolism*
		                        			
		                        		
		                        	
8.Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.
Xiangyu ZHAO ; Haotian WU ; Yifei CHENG ; Zhengli XU ; Yuhong CHEN ; Yingjun CHANG ; Yu WANG ; Xiaohui ZHANG ; Lanping XU ; Xiaojun HUANG
Chinese Medical Journal 2023;136(16):2011-2013
9.Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
Ying ZHANG ; Jiang Wen QU ; Min Na ZHENG ; Ya Xing DING ; Wei CHEN ; Shao Dong YE ; Xiao Yan LI ; Yan Kun LI ; Ying LIU ; Di ZHU ; Can Rui JIN ; Lin WANG ; Jin Ye YANG ; Yu ZHAI ; Er Qiang WANG ; Xing MENG
Biomedical and Environmental Sciences 2023;36(7):614-624
		                        		
		                        			OBJECTIVE:
		                        			To investigate whether Omicron BA.1 breakthrough infection after receiving the SARS-CoV-2 vaccine could create a strong immunity barrier.
		                        		
		                        			METHODS:
		                        			Blood samples were collected at two different time points from 124 Omicron BA.1 breakthrough infected patients and 124 controls matched for age, gender, and vaccination profile. Live virus-neutralizing antibodies against five SARS-CoV-2 variants, including WT, Gamma, Beta, Delta, and Omicron BA.1, and T-lymphocyte lymphocyte counts in both groups were measured and statistically analyzed.
		                        		
		                        			RESULTS:
		                        			The neutralizing antibody titers against five different variants of SARS-CoV-2 were significantly increased in the vaccinated population infected with the Omicron BA.1 variant at 3 months after infection, but mainly increased the antibody level against the WT strain, and the antibody against the Omicron strain was the lowest. The neutralizing antibody level decreased rapidly 6 months after infection. The T-lymphocyte cell counts of patients with mild and moderate disease recovered at 3 months and completely returned to the normal state at 6 months.
		                        		
		                        			CONCLUSION
		                        			Omicron BA.1 breakthrough infection mainly evoked humoral immune memory in the original strain after vaccination and hardly produced neutralizing antibodies specific to Omicron BA.1. Neutralizing antibodies against the different strains declined rapidly and showed features similar to those of influenza. Thus, T-lymphocytes may play an important role in recovery.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Antibodies, Neutralizing
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			SARS-CoV-2
		                        			;
		                        		
		                        			Breakthrough Infections
		                        			;
		                        		
		                        			COVID-19 Vaccines
		                        			;
		                        		
		                        			COVID-19
		                        			;
		                        		
		                        			T-Lymphocytes
		                        			;
		                        		
		                        			China/epidemiology*
		                        			;
		                        		
		                        			Antibodies, Viral
		                        			
		                        		
		                        	
            

Result Analysis
Print
Save
E-mail